Dauch Corporation

Dauch Corporation is a clinical-stage biotechnology company that develops treatments for complex diseases using compositions of endogenous metabolic modulators (EMMs). The company's product candidates consist of multiple EMMs engineered in specific combinations and ratios to impact multiple biological pathways simultaneously. Dauch Corporation's pipeline includes lead therapeutic candidates for treating Long COVID (also known as Post COVID-19 Condition and Post-Acute Sequelae of COVID-19, or "PASC") associated fatigue, and for treating non-alcoholic steatohepatitis (NASH). Through its discovery platform, Dauch Corporation has designed product candidates primarily composed of amino acids and their derivatives, which have a general history of safe use. The orally administered EMM compositions tested clinically to date have demonstrated the potential to produce multifactorial effects in initial Clinical Studies. In December 2022, Dauch Corporation announced the discontinuation of its EMMPACT Phase 2b clinical trial of AXA1125 for NASH to concentrate on AXA1125 for Long COVID associated fatigue. The company also announced a corporate restructuring and initiated a process to explore strategic alternatives to maximize shareholder value, engaging an investment bank as a strategic advisor for this process.